Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
出版年份 2020 全文链接
标题
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
作者
关键词
-
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 85, Issue 5, Pages 917-930
出版商
Springer Science and Business Media LLC
发表日期
2020-04-09
DOI
10.1007/s00280-020-04066-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
- (2019) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
- (2018) Robert J. Nichols et al. NATURE CELL BIOLOGY
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
- (2016) Carla S Verissimo et al. eLife
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
- (2014) H. S. Hochster et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma
- (2014) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
- (2014) Gerald Falchook et al. INVESTIGATIONAL NEW DRUGS
- Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer
- (2014) A. Jo Chien et al. JOURNAL OF CLINICAL ONCOLOGY
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer
- (2013) Zhongzhen Guan et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
- (2012) Michael Untch et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors
- (2011) H. K. Chew et al. ANNALS OF ONCOLOGY
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now